39 results on '"Robillard, Nelly"'
Search Results
2. Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma
3. Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation
4. Reactive Plasmacytoses Are Expansions of Plasmablasts Retaining the Capacity to Differentiate Into Plasma Cells
5. CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy
6. In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)
7. Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study
8. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study
9. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial
10. Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome
11. Phase 1 Dose-Escalation Study of 90yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
12. Value of Day 21 Flow Cytometry Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia (ALL) for Early Identification of Good Responders
13. Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study
14. CD180 Expression in B-Cell Lymphomas: A Multicenter Geil Study
15. Relative Stability Of Plasma Cells Immunophenotype In Multiple Myeloma Over Time
16. Paired Immunophenotype Comparison Of Diagnosis and Relapse Samples In B-Lineage Acute Lymphoblastic Leukemia
17. Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain
18. BCR-ABL1 Molecular Remission After 90y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22+ Ph+ B-ALL: A Potential New Treatment Paradigm
19. Higher HHV-6 Reactivation After Cord Blood Allo-SCT Is Not Related to HHV-6 Cell Receptor CD46 Expression
20. Interest of Early Determination of Bone Marrow MRD by a Sensitive 6-Color Flow Cytometry in the Evaluation of Response: The Experience of the CLL2007FMP, An Intergroup Phase III Randomized Multicentric Trial Comparing Fludarabine Cyclophosphamide (FC) and Rituximab (FCR) Versus FC and MabCampath (FCCam) in Previously Untreated B-Chronic Lymphocytic Leukemia Patients
21. Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program
22. Trastuzumab (Herceptin®) for Treatment of Refractory/Relapsed HER2 Positive Adult B-ALL: Results of a Phase II GRAALL Study
23. A Single-Tube Seven-Colour Flow Cytometry Assay for Detection of Minimal Residual Disease In Myeloma.
24. CLL2007FMP, a Phase III Randomized Multicentric Trial of the French Cooperative Group On CLL and WM (FCGCLL/MW) and the 'Groupe Ouest-Est D'etudes Des Leucémies Aigües Et Autres Maladies Du Sang' (GOELAMS): Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Yields a Significantly Better Response Than Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) In Previously Untreated B-Chronic Lymphocytic Leukemia Patients as Evaluated by a Sensitive 6 Color Flow Cytometry MRD
25. Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group.
26. Phenotypic characterization of the human myeloma cell growth fraction
27. The Coexpression of CD11a and CD45bright Is the Hallmark of Proliferating Myeloma Cells.
28. Overexpression of Her-2/neu Is Observed in One Third of Adult B-ALL Patients and Is Associated with Chemoresistance in These Patients.
29. Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma.
30. Mcl-1 Is Overexpressed in Multiple Myeloma and Correlates with Disease Severity.
31. Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events
32. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
33. Mantle cell lymphoma with t(11;14) and unmutated or mutated VHgenes expressesAIDand undergoes isotype switch events
34. Reproducible Obtaining of Human Myeloma Cell Lines as a Model for Tumor Stem Cell Study in Human Multiple Myeloma
35. Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study
36. Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22+B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study
37. Phase 1 Dose-Escalation Study of 90yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22+B-Cell Acute Lymphoblastic Leukemia (B-ALL)
38. BCR-ABL1 Molecular Remission After 90y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22+Ph+B-ALL: A Potential New Treatment Paradigm
39. Expression of CD28 and CD40 in Human Myeloma Cells: A Comparative Study With Normal Plasma Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.